Compare FWRD & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | HELP |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.4M | 279.9M |
| IPO Year | 2024 | N/A |
| Metric | FWRD | HELP |
|---|---|---|
| Price | $8.70 | $4.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $37.50 | ★ $51.50 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 05-07-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.65 | $4.29 |
| 52 Week High | $32.47 | $8.55 |
| Indicator | FWRD | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 25.27 | 38.85 |
| Support Level | N/A | $4.40 |
| Resistance Level | $30.86 | $6.26 |
| Average True Range (ATR) | 1.49 | 0.31 |
| MACD | -1.22 | -0.05 |
| Stochastic Oscillator | 1.04 | 3.83 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.